Areas of focus

We have a strong history of addressing some of the most critical unmet clinical needs and are well placed to help societies across Europe address today’s health challenges.

At Shionogi, we focus on some of the most pressing healthcare challenges through scientific expertise, policy engagement and a patient-centred approach. By bringing together our work in infectious diseases, health security and rare diseases, we aim to improve patient outcomes, support public health systems and help create a healthier future for people and communities around the world.
  • Infectious diseases: Advancing innovation in infectious diseases

    Infectious diseases continue to pose significant challenges for patients and healthcare systems worldwide. Through work in antimicrobial resistance (AMR), HIV, serious-fungal infections, respiratory viral infections and other areas of unmet medical need, Shionogi is committed to improving patient outcomes and advancing public health.

    Learn More
  • Health Security: Strengthening health security

    Health threats do not respect borders. Through scientific innovation, policy engagement and collaboration with public-health stakeholders, Shionogi supports stronger pandemic preparedness, health emergency preparedness and response, and resilience against cross-border health threats.

    Learn More
  • Rare Diseases: Advancing rare disease care

    We are committed to addressing unmet medical need in rare diseases through scientific expertise, patient engagement and collaboration across the healthcare ecosystem, with a focus on earlier diagnosis, access to treatment, and patient-centred care.

    Learn More

Diseases and therapy areas affecting quality of life, with high social impact

In the area of women's health we have created a therapy to combat vulvar and vaginal atrophy. This condition occurs post-menopause and results in thinning of vaginal epithelial cells, reduced elasticity, and decreased vaginal secretion due to declining oestrogen levels.

 

Within our work to improve the quality of life for people who suffer from pain, we developed a medication for the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative.  

 

We continue to focus on addressing areas of unmet need, such as hearing loss, dementia, obesity, sleep disorders and paediatric care.

 

 

NP-EU-NP-0368 | June 2026